Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Tengteng Yu"'
Autor:
Jian Cui, Tengteng Yu, Rui Lv, Jiahui Liu, Huishou Fan, Wenqiang Yan, Jingyu Xu, Chenxing Du, Shuhui Deng, Weiwei Sui, Matthew Ho, Yan Xu, Kenneth C. Anderson, Xifeng Dong, Lugui Qiu, Gang An
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Deeper depth of response (DpR) after induction therapy, especially gain of negative minimal residual disease (MRD), has been linked to prolonged survival in multiple myeloma (MM). However, flow-MRD examination focuses on the numbers but n
Externí odkaz:
https://doaj.org/article/d2351facc29a43f9a0ab3bba64b55009
Autor:
Jian Cui, Rui Lv, Tengteng Yu, Wenqiang Yan, Jingyu Xu, Huishou Fan, Lingna Li, Yuntong Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Shuhua Yi, Dehui Zou, Lugui Qiu, Gang An
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
The deletion of chromosome 17p (del(17p)) is considered a crucial prognostic factor at the time of diagnosis in patients with multiple myeloma (MM). However, the impact of del(17p) on survival at different clonal sizes at relapse, as well as the patt
Externí odkaz:
https://doaj.org/article/02fe9344e4b941c19f0ef2b86f34f3bc
Autor:
Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Kimberly Aardalen, Adwait Oka, Joni Lam, Mike Daley, Haihui Lu, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 8, Pp 1-10 (2022)
Abstract We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs). GSIs-induced membrane BCMA (mBCMA) accum
Externí odkaz:
https://doaj.org/article/18630a073f974d81b53cefcf6ea2de9d
Autor:
Zhen Yu, Xiaojing Wei, Lanting Liu, Hao Sun, Teng Fang, Lu Wang, Ying Li, Weiwei Sui, Kefei Wang, Yi He, Yaozhong Zhao, Wenyang Huang, Gang An, Fancui Meng, Changjiang Huang, Tengteng Yu, Kenneth C. Anderson, Tao Cheng, Lugui Qiu, Mu Hao
Publikováno v:
EBioMedicine, Vol 78, Iss , Pp 103950- (2022)
Summary: Background: Multiple myeloma (MM) is still an incurable malignancy of plasma cells. Proteasome inhibitors (PIs) work as the backbone agent and have greatly improved the outcome in majority of newly diagnosed patients with myeloma. However, d
Externí odkaz:
https://doaj.org/article/271b810c490745ecb2266666d34c4ea7
Autor:
Wenchao Lu, Yao Liu, Yang Gao, Qixiang Geng, Deepak Gurbani, Lianbo Li, Scott B. Ficarro, Cynthia J. Meyer, Dhiraj Sinha, Inchul You, Jason Tse, Zhixiang He, Wenzhi Ji, Jianwei Che, Audrey Y. Kim, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Jarrod A. Marto, Kenneth D. Westover, Tinghu Zhang, Nathanael S. Gray
Publikováno v:
Journal of Medicinal Chemistry. 66:3356-3371
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd86b65b4fd779fd0cc4c049897206f6
https://doi.org/10.1021/acs.jmedchem.2c01834
https://doi.org/10.1021/acs.jmedchem.2c01834
Autor:
Shaowei Qiu, Shuang Liu, Tengteng Yu, Jing Yu, Min Wang, Qing Rao, Haiyan Xing, Kejing Tang, Yinchang Mi, Jianxiang Wang
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Abstract Background As the important suppressor of P53, iASPP is found to be overexpressed in leukemia, and functions as oncogene that inhibited apoptosis of leukemia cells. Sertad1 is identified as one of the proteins that can bind with iASPP in our
Externí odkaz:
https://doaj.org/article/16f64e89a2b746eb90b37a97ca5d2221
Autor:
Mu Hao, Fenghuang Zhan, Lugui Qiu, Kenneth C. Anderson, Guido Tricot, Yu-Tzu Tai, Gang An, Dehui Zou, Shuhui Deng, Wen Zhou, Xiaojing Wei, Jie Xu, Zhongqing Li, Lei Zhao, Lanting Liu, Zhen Yu, Weiwei Sui, Xiaoke Ma, Chenxing Du, Tengteng Yu
Multiple myeloma remains incurable due to the persistence of a minor population of multiple myeloma cells that exhibit drug resistance, which leads to relapsed and/or refractory multiple myeloma. Elucidating the mechanism underlying drug resistance a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1900ef71b3962ba8f724fda6696eda65
https://doi.org/10.1158/1541-7786.c.6541417.v1
https://doi.org/10.1158/1541-7786.c.6541417.v1
Autor:
Mu Hao, Fenghuang Zhan, Lugui Qiu, Kenneth C. Anderson, Guido Tricot, Yu-Tzu Tai, Gang An, Dehui Zou, Shuhui Deng, Wen Zhou, Xiaojing Wei, Jie Xu, Zhongqing Li, Lei Zhao, Lanting Liu, Zhen Yu, Weiwei Sui, Xiaoke Ma, Chenxing Du, Tengteng Yu
Supplementary Fig.1. PHF19 gene expression is associated with poor prognosis in myeloma patients. Supplementary Fig.2. Enhanced PHF19 expression in OCI-My5 cells decrease drug sensitivity. Supplementary Fig.3. PHF19 interacts with EZH2. Supplementary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7375ad16fda495250dcaa4087e22a5d0
https://doi.org/10.1158/1541-7786.22516570.v1
https://doi.org/10.1158/1541-7786.22516570.v1
Autor:
Yu-Tzu Tai, Kenneth C. Anderson, Nikhil Munshi, Krista Kinneer, Lugui Qiu, Gang An, Shih-Feng Cho, Phillip A. Hsieh, Liang Lin, Yuyin Li, Kenneth Wen, Hailin Chen, Tengteng Yu, Jiye Liu, Su Wang, Lijie Xing
Supplementary materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a55db04fc154e40a6838e71bb3ccad
https://doi.org/10.1158/1078-0432.22481021.v1
https://doi.org/10.1158/1078-0432.22481021.v1
Autor:
Yu-Tzu Tai, Kenneth C. Anderson, Nikhil Munshi, Krista Kinneer, Lugui Qiu, Gang An, Shih-Feng Cho, Phillip A. Hsieh, Liang Lin, Yuyin Li, Kenneth Wen, Hailin Chen, Tengteng Yu, Jiye Liu, Su Wang, Lijie Xing
Purpose:Efforts are required to improve the potency and durability of CD38- and BCMA-based immunotherapies in human multiple myeloma. We here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects triggered by BCMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::697ebeaef990a235523df8478a91e3ca
https://doi.org/10.1158/1078-0432.c.6530600
https://doi.org/10.1158/1078-0432.c.6530600